A mélange of new treatments awaiting approval and a lack of patient support are driving down drug utilization for Gilead's HCV blockbuster, according to a new study.
Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.
Healthcare workers seek out health-related information on their own time, and through internet connections other than ones offered by their employers.
The numbers folks at the Centers for Medicare and Medicaid Services anticipate sluggish growth in US healthcare spend, but prescriptions look ready to take off.
The latest data shows an overall widening of the US.
The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.
Tech site Venturebeat, citing anonymous sources, says doctors are too overwhelmed and weary to evaluate how many steps you took this weekend.
African-American women had the highest risk of being diagnosed with diabetes—55%. Hispanic men and women were close behind, carrying a 50% risk of being diagnosed with diabetes.
A study indicates consumers stop using them at the six-month mark.
Half-measures, like diabetes educational materials without a part B, fared poorly.
The pharma payment verification site has been temporarily shut down by CMS due to incorrect information, ProPublica reported today.
A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.
Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like meals, travel, gifts, consulting and research
Generics made up almost 75% of prescriptions in the United Kingdom last year.
An international AIDS conference this weekend kicked off a new battle in the war against hepatitis C: demonstrating high cure rates in those who are co-infected.
The rate of decrease in industry's budget for continuing medical education (CME) slowed last year.
Industry reined in commercial support for CME in 2013—the sixth consecutive annual decrease—data released today by the ACCME show.
German healthcare data from 2004 through 2010 across a data set that included 146,000 patients shows dementia surfaced later among Actos patients.
The FDA began its drug review at a median time of 103 days sooner than the EMA. Being first, researchers found, often resulted in quicker approval.
Prices for some generics are rising, thanks to limited competition.
Credit card and loyalty program purchases will help Carolinas HealthCare System flag potential patient behavior issues.
Zogenix is working on a less easily abused formulation of its controversial prescription painkiller.
The Centers of Disease Control reports that prescribers wrote enough painkiller prescriptions to give one bottle to every adult in the US in 2012.
The networking site's emotion experiment rankles some in the science and political communities.
IMS is offering $520 million cash to add Cegedim's CRM and strategic data business. Cegedim says it will use the money to pay down debt.
EvaluatePharma's World Preview 2014 has pharma soaring to new lucrative heights in six years' time, buoyed by biologics and a formidable pipeline.
Phase III results showing improved lung function among cystic fibrosis patients using a combination of Kalydeco and lumacaftor means drugmaker Vertex is filing the two-part drug for FDA approval during the fourth quarter.
Platform lets pharma firms mine big data, and monitor whether millions spent on ad campaigns or medical education are having the desired effect
Gene mutations lead researchers to rethink ways to protect the heart.
An Alzheimer's Association survey finds 59% think the degenerative disease is just part of aging.